

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/869198

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE.	PRIORITY DATE CLAIMED
PCT/US99/30503	December 21, 1999	December 22, 1998
TITLE OF INVENTION		
VASCULAR ENDOTHELIAL GROWTH FACTOR-X		
APPLICANT(S) FOR DO/EO/US :		
GORDON et al.		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment with version to show changes made.
 A SECOND or SUBSEQUENT preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information: **Copy of the International Search Report; Copy of Notification of Transmittal of the International Preliminary Examination Report; Sequence Disk; Sequence Listing; Associate Power of Attorney; Verified Statement Under 37 CFR 1.821(f).**

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.			
09/869198		PT/US99/30503		
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):		CALCULATIONS PTO USE ONLY		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1070.00				
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$930.00				
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.455(a)(2)) paid to USPTO..... \$790.00				
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$720.00				
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$98.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 930.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	69 - 20 =	49	x \$18.00	\$ 882.00
Independent claims	54 - 3 =	51	x \$80.00	\$ 4080.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 0
TOTAL OF ABOVE CALCULATIONS =		\$		
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		+ \$ 0		
SUBTOTAL =		\$ 5892.00		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$ 0		
TOTAL NATIONAL FEE =		\$ 5892.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$		
TOTAL FEES ENCLOSED =		\$ 5892.00		
		Amount to be refunded:	\$	
		charged:	\$ 5892.00	
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>10-0750/JAB-1463/MHM</u> in the amount of \$5892.00 cover the above fee. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>10-0750/JAB-1463/MHM</u>. A duplicate copy of this sheet is enclosed.</p>				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO:		 Signature Myra H. McCormack Reg. No. 36,602 Attorney for Applicants June 21, 2001		
Philip S. Johnson, Esq. Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 USA				

J604 Rec'd PCT/PTO 21 JUN 2001
09/869198
DOCKET NO. JAB-1463

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GORDON et al.

For : VASCULAR ENDOTHELIAL GROWTH FACTOR-X

Express Mail Certificate

"Express Mail" mailing number: EL710607465US

Date of Deposit: June 21, 2001

I hereby certify that this complete application, including specification pages, claims, informal drawings, Declaration and Power of Attorney, and Assignment, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Karen Hall-Morgan

(Typed or printed name of person mailing paper or fee)

Karen Hall Morgan

(Signature of person mailing paper or fee)

09/869198

JC18 Rec'd PCT/PTO 21 JUN 2001

DOCKET NO. JAB-1463

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: GORDON et al.

For: VASCULAR ENDOTHELIAL GROWTH FACTOR-X

Filed: June 21, 2001

Serial No: TBD

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I hereby verify that the computer readable diskette enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

Myra McCormack
Myra H. McCormack
Reg. No. 36,602

DATE: June 21, 2001